应收账款高企，这家A股出手：拟3亿现金收购！

Core Viewpoint - The company intends to acquire 72.863% of Kanglu Bio for 291 million yuan, with potential further acquisitions to increase ownership to 82% for a total of 328 million yuan [1][3]. Group 1: Acquisition Details - The acquisition will be a cash transaction, with the company currently having less than 400 million yuan in cash as of the end of Q1 this year [3][7]. - The acquisition employs a differentiated pricing strategy, with significant price variations among different venture capital institutions involved [9][12]. - The valuation of Kanglu Bio reflects a 226.53% increase in the value of the parent company's equity, amounting to an increase of 277 million yuan [10]. Group 2: Financial Performance of Kanglu Bio - Kanglu Bio's revenue for 2024 is projected to be less than 100 million yuan, with accounts receivable exceeding 40 million yuan, indicating potential revenue quality issues [3][10]. - As of the end of 2024, Kanglu Bio's total assets were 153 million yuan, with net assets of 116 million yuan [10]. - The company's revenue and net profit for 2024 are expected to be 97.3 million yuan and 16.96 million yuan, respectively, with significant accounts receivable levels [10][11]. Group 3: Strategic Rationale - The acquisition is expected to create synergies in product offerings, enhancing the company's capabilities in molecular pathology and cancer diagnostics [5][6]. - The company aims to leverage its extensive sales channels across 31 provinces in China, primarily targeting tertiary hospitals, which aligns with Kanglu Bio's existing customer base [6]. - Collaborative research and development efforts are anticipated to improve efficiency and innovation in diagnostic solutions, benefiting both companies [6]. Group 4: Company Background - The company, established in 2003, specializes in high-end in vitro diagnostic products and was listed on the Growth Enterprise Market in April 2017 [12]. - Recent financial performance has been challenging, with consecutive years of declining revenue and net profit, dropping from 161 million yuan in 2021 to 34.53 million yuan in 2024 [12][14].